Graft Dysfunction Clinical Trial
Official title:
Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK
BKV nephropathy (BKV) is one of the most frequent complications of kidney transplantation.
In the absence of specific anti-BKV treatment, pre-emptive reduction of immunosuppression is
the main strategy that has proven effective in reducing the risk of BKVN. However, it
exposes a transplant rejection risk estimated between 4 and 14% according to studies.
Despite the pre-emptive reduction of immunosuppression, a significant number of patients
continue to progress towards BKVN suggesting that pre-emptive strategy is late. It's
therefore urgent to develop new prognostic markers to identify earlier and more effectively
patients with a higher risk of developing BKVN.
n/a
Observational Model: Cohort
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01564095 -
TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05031052 -
Normothermic Machine Perfusion (NMP) Versus Static Cold Storage (SCS) in Human Kidney Transplantation
|
N/A | |
| Completed |
NCT04420897 -
The Effect of Intraoperative Arterial Oxygen Pressures on Early Post-Operative Patient and Graft Survival in Living Donor Kidney Transplantation
|
||
| Recruiting |
NCT03808324 -
Heart Failure After Heart Transplantation Due to Chronic Rejection
|
N/A | |
| Completed |
NCT02096107 -
Novartis Everolimus Transition
|
Phase 4 | |
| Recruiting |
NCT03786991 -
EPI-STORM: Cytokine Storm in Organ Donors
|